

May 2, 2022

Ropivacaine Hydrochloride Injection, USP 10 mg/mL Allocation Update

Dear Valued Customer,

Fresenius Kabi Canada would like to provide the following updates regarding our **Ropivacaine Hydrochloride Injection, USP 10 mg/mL** effective **May 2, 2022**:

Due to production delays, the allocation for our **Ropivacaine Hydrochloride Injection, USP 10 mg/mL Ampoule 20 mL** will be reduced. Contract customers will be allocated **50% of historical monthly demand**.

Allocations for our **Ropivacaine Hydrochloride Injection, USP 10 mg/mL Ampoule 10 mL** will be increased to cover **100% of historical 10 mL monthly demand plus 50% of 20 mL demand on a mL per mL basis**.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Supply Status May 2022
02439409	ABA1847	974882	124915	Ropivacaine Hydrochloride Injection, USP 10 mg/mL Ampoule 20 mL	Allocations reduced to cover 50% of monthly demand
02439409	ABA1846	974894	124903	Ropivacaine Hydrochloride Injection, USP 10 mg/mL Ampoule 10 mL	Allocations increased to cover 100% of 10 mL demand plus 50% of 20 mL demand on mL:mL basis

We recognize the difficulties and inconvenience that you may encounter as a result of these allocations, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,



George Shamsoun
Associate Director – Marketing, IV Drugs
george.shamsoun@fresenius-kabi.com